2.5 mcg/mL Fentanyl Citrate and 0.0312% Bupivacaine HCl (Preservative Free) in 0.9% Sodium Chlori...

FDA Drug Recall #D-1403-2016 — Class II — May 5, 2016

Recall Summary

Recall Number D-1403-2016
Classification Class II — Moderate risk
Date Initiated May 5, 2016
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Pharmedium Services, LLC
Location Lake Forest, IL
Product Type Drugs
Quantity 105 bags

Product Description

2.5 mcg/mL Fentanyl Citrate and 0.0312% Bupivacaine HCl (Preservative Free) in 0.9% Sodium Chloride, 250 mL in 250 mL Hospira LifeCare Bag, Service Code 2H9195, Rx Only, Compounded by PharMEDium Services, LLC, Memphis, TN 36141, NDC 61553-195-50

Reason for Recall

Presence of Particulate Matter: API contaminated with glass particulate was used to produce sterile injectable drugs.

Distribution Pattern

Nationwide

Lot / Code Information

Lot Number 160890247M , Exp. Date 6/28/2016 ; Lot Number 160380151M , Exp. Date 5/8/2016 ; Lot Number 160490238M , Exp. Date 5/19/2016 ; Lot Number 160550208M , Exp. Date 5/25/2016 ; Lot Number 160610062M , Exp. Date 5/30/2016 ; Lot Number 160630184M , Exp. Date 6/2/2016 ; Lot Number 160700191M , Exp. Date 6/9/2016 ; Lot Number 160750045M , Exp. Date 6/13/2016 ; Lot Number 160770156M , Exp. Date 6/16/2016 ; Lot Number 160910163M , Exp. Date 6/30/2016 ; Lot Number 160810279M , Exp. Date 6/20/2016 ;

Other Recalls from Pharmedium Services, LLC

Recall # Classification Product Date
D-1087-2020 Class II rocuronium Bromide, 10 mg per mL, 50 mg per 5 m... Mar 16, 2020
D-1088-2020 Class II ePHEDrine Sulfate, 5 mg per mL, 25 mg per 5 mL ... Mar 16, 2020
D-1085-2020 Class II fentaNYL Citrate 10 mcg per mL, 2,500 mcg per 2... Mar 16, 2020
D-1082-2020 Class II nICARdipine HCl (0.1 mg/mL) 1 mg/10mL, in 0.9%... Mar 16, 2020
D-1083-2020 Class II rocuronium Bromide 10 mg per mL 50 mg per 5 mL,... Mar 16, 2020

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.